Earnings Call Summary | Protagenic Therapeutics(PTIX.US) Q4 2023 Earnings Conference
Earnings Call Summary | Protagenic Therapeutics(PTIX.US) Q4 2023 Earnings Conference
The net loss for Q4 amounted to $1.2 million, an increase compared to a net loss of $656,000 in the same quarter of the previous year. The company ended the year with cash and cash equivalents of $4.1 million.The following is a summary of the Protagenic Therapeutics, Inc. (PTIX) Q4 2023 Earnings Call Transcript:
以下是Protagenic Therapeutics, Inc.（PTIX）2023年第四季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
Protagenic Therapeutics reported an increase in Research and Development (R&D) spending to $1.0 million in Q4 2023, a surge of 301% compared to the same period of the previous year.
General and Administrative spending was reduced by 50% to $201,000 in Q4 2023 due to no stock options being issued during the quarter.
The net loss for Q4 amounted to $1.2 million, an increase compared to a net loss of $656,000 in the same quarter of the previous year. The company ended the year with cash and cash equivalents of $4.1 million.
Protagenic Therapeutics報告稱，2023年第四季度的研發（R&D）支出增加到100萬美元，與去年同期相比增長了301％。
由於該季度沒有發行股票期權，2023年第四季度的一般和管理支出減少了50％，至201,000美元。
第四季度的淨虧損爲120萬美元，與去年同期的淨虧損656,000美元相比有所增加。該公司在年底的現金及現金等價物爲410萬美元。
Business Progress:
業務進展：
2023 marked a significant year for Protagenic Therapeutics, witnessing the commencement of their maiden clinical trial of their flagship product PT00114, anticipated to aid millions of patients suffering from depression, chronic anxiety, PTSD, or drug addiction.
The initiation of the first in-human trial of PT00114 has helped transition the company into a clinical stage company.
The focus for 2024 will be to progress their Phase 1 program efficiently and prepare for proof-of-concept efficacy studies in anxiety, depression, and other stress-related conditions.
2023 年對Protagenic Therapeutics來說是重要的一年，他們開始了旗艦產品 PT00114 的首次臨床試驗，預計該產品將幫助數百萬患有抑鬱症、慢性焦慮、創傷後應激障礙或吸毒成癮的患者。
PT00114 的首項人體試驗的啓動幫助該公司轉變爲一家臨床階段的公司。
2024年的重點將是有效推進其第一階段計劃，爲焦慮、抑鬱和其他壓力相關疾病的概念驗證療效研究做準備。
More details: Protagenic Therapeutics IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。
